Tiny magnetic particles may help assess heart treatments

Researchers showed that injecting immune cells containing magnetic particles into the bloodstream was safe and did not interfere with cell function. Magnetic resonance imaging (MRI) scans can then track the cells moving through the body.

"This could change how we assess new treatments affecting inflammation and the outcome of a heart attack or heart failure," said Jennifer Richards, M.D., lead author and vascular surgeon at the University of Edinburgh's Centre for Cardiovascular Science in Scotland.

With stem cell therapy, doctors can adapt blood cells to fight disease. But when developing these therapies, it's hard to tell exactly where cells go and how many go where they are supposed to. Safely tracking them would help scientists better understand how new therapies combat heart disease.

Other tracing methods expose patients to excess radiation or only allow cells to be tracked for a few hours. But MRI scans use no radiation, and cells containing the particles can be monitored for at least a week.

Using test tubes, Richards' team first determined that magnetically labeled blood cells move and thrive like normal ones.

Then, they did four small-scale tests in humans: Six people were successfully given three thigh muscle injections of unlabeled cells, magnetically labeled cells, and an injection of just the magnetic material. The labeled cells were traceable up to seven days later. Two people were given six increasingly larger doses of magnetically labeled blood cells through a vein, and they had no negative effects. 12 people got intravenous injections of the labeled blood cells – six getting a high dose and six a low dose – which were traceable by MRI a week later. To test how well the cells travel to inflammation sites, one person was injected with the labeled blood cells, which were successfully followed by an MRI as the cells moved to an inflamed area of skin on the thigh. "This demonstrates that this method may be useful to facilitate the development of cell-based therapies in the future," Richards said.

Richards said more human tests are needed before researchers can regularly use magnetically labeled cells.

INFORMATION:

Co-authors and disclosures are on the manuscript.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

END